Science Policy Recap: February 9, 2017

While the executive order on immigration continues to affect scientists, a coalition of public interest groups is suing the Trump administration, alleging that the president’s executive order on regulations “exceeds [his] constitutional authority.”

Written byJoshua A. Krisch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, THE WHITE HOUSEPresident Donald Trump’s executive order on immigration continues to affect scientists. The Atlantic described how one team of scientists at Harvard University is coping with order-associated travel restrictions. Pardis Sabeti, the head of the lab, is a former Iranian refugee. She recently posted a picture of her Iranian colleagues on social media. “I just wanted to show the faces of the types of people they’re trying to ban,” she told The Atlantic. “They’re off-the-charts brilliant, kind, humble, and hard-working. Last night, they were all here working in the lab, with the Super bowl on in the background.”

Criticism of the immigration order continues to trickle in. This week, 12 doctors’ groups formally protested the ban, according to MedPage Today, and pharma executives are expected to sign their own statement shortly, STAT News added. Nearly 100 biotechnology executives have also signed a letter opposing the executive order, Forbes reported. The letter, due to be published in Nature Biotechnology, notes that more than half of the biomedical researchers in the U.S. are foreign-born.

Meanwhile, STAT reported, a coalition of public interest groups is suing the Trump administration to block another executive order—one telling federal agencies to repeal two regulations for every new one issued. “The Executive Order exceeds President Trump’s constitutional authority, violates his duty under the Take Care Clause of the Constitution, and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies